PTX3

Across TCGA pan-cancer cohorts, PTX3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PTX3 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PTX3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTX3 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where PTX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.315	0.961	.003	33	view →
PDAC	OS	Median	III,IV	0.306	0.592	.008	27	view →
LUAD	OS	Tertile	III,IV	0.412	0.842	.010	18	view →
GBM	DFS	Quartile	All	0.255	0.538	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PTX3–CCRCC (DFS)

Open the CCRCC breakdown →